FATE

Insider Trades

Name	Value	Action	Price	Current Price
Tahl CindySee Remarks $48k25.6k shares SellMay 20, 2026 $1.88 --
Tahl CindyInsider $48k25.6k shares SellMay 20, 2026 $1.88 --
Valamehr BahramDirector, Officer: President And CEO $54k28.9k shares SellMay 20, 2026 $1.88 --
Valamehr BahramInsider $54k28.9k shares SellMay 20, 2026 $1.88 --
Tahl CindySee Remarks $11k10.6k shares SellJan 9, 2026 $1.06 --
Valamehr BahramDirector, Officer: President And CEO $5.6k5.2k shares SellJan 9, 2026 $1.07 --

News

globenewswire.comFate Therapeutics Appoints Laura Hamill to Board of Directorsglobenewswire.comJun 15

globenewswire.comFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meetingglobenewswire.comJun 4

globenewswire.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 2

globenewswire.comFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meetingglobenewswire.comJun 1

Trade FATE

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

CEO: Bahram Valamehr
IPO Date: Oct 1, 2013

Market Data

Open: $2.00
High: $2.14
Low: $1.93
Volume: 4.1M
Avg Volume: 3M
52W High: $2.88
52W Low: $0.91

Valuation

Market Cap: $244M
Enterprise Value: $281M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-112M
Revenue: $6.6M
Net Income: $-136M
Cash: $47M
Debt: $78M

Events

EarningsAug 11

EPS est. -0.28